个人简介：

Tao Huang, PhD, JD,President and CEO

Tao is NeuCyte’s President and CEO and oversees management, focusing on corporate strategy, business development, finance, and drug discovery. He is also a co-founder of NeuCyte. Prior to NeuCyte, Tao practiced law at several U.S. law firms and advised companies and investors in the biotechnology and pharmaceutical industries on patent prosecution, licensing, litigation, VC financing, and M&A.

Tao received his PhD in Biochemistry from Peking Union Medical College, where he studied the function of the Fragile X Syndrome gene (fmr1) during development. Following his graduate studies, Tao got his postdoctoral training at the University of Colorado School of Medicine and Princeton University. Tao later gained interest in law and received his JD from the University of Michigan Law School.

Outside of the lab, Tao enjoys spending time with his family and playing with his two daughters. He also enjoys reading, especially biographies and history, and going on hikes on the Bay Trail.

公司简介：

NeuCyte is an early-stage biotechnology company solely focused on neurological diseases. With the expertise on advancing the drug discovery process by using cell based target identification and drug discovery platforms, NeuCyte puts an emphasis on the biology insight of the disorders to develop novel drugs that truly address the altered biological state of the patients.

Our technology accelerates the lead drug identification and optimization process. Our unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity.